ArticleTranslational vision science & technology2022
Rates of Glaucoma Progression Derived from Linear Mixed Models Using Varied Random Effect Distributions.
Article in Translational vision science & technology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Visual Field Outcomes in the Primary Tube Versus Trabeculectomy Study.Ophthalmology · 2024Trial
- Long-term visual field progression after Ex-PRESS implantation versus trabeculectomy in refractory glaucoma.International ophthalmology · 2026Article
- Fast Progressors in Primary Open-Angle Glaucoma: A 5-Year Visual Field Index-Based Classification in a Real-World Cohort.Ophthalmology and therapy · 2026Article
- Loss to follow-up and increase in cup-to-disc ratio among glaucoma patients in the IRIS Registry.Canadian journal of ophthalmology. Journal canadien d'ophtalmologie · 2026Article
- Proportion of Fast Progressors in the Central versus Global Visual Field Across Varying Glaucoma Severity Groups.American journal of ophthalmology · 2026Article
- Using the Rate of Global and Pointwise Microperimetry Change to Predict Structural Conversion in Intermediate Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Inefficacy of Longitudinal Cup-to-Disc Ratio Measurements in Identifying Glaucoma Progression.American journal of ophthalmology · 2025Article
- Differential Impact of Central and Global Visual Field Progression on Quality of Life in Glaucoma.American journal of ophthalmology · 2025Article
- Joint Modeling of Longitudinal Visual Field Changes and Time to Detect Progression in Glaucoma Patients: A Secondary Data Analysis.Iranian journal of medical sciences · 2025Article
- Peripherex Home Visual Field Demonstrates High Test-Retest Reliability, Validity.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Impact of race and ethnicity on glaucoma progression detection by perimetry and optical coherence tomography.Scientific reports · 2024Article
- Association Between Greater Social Vulnerability and Delayed Glaucoma Surgery.American journal of ophthalmology · 2024Article
- Impact of Race and Ethnicity on Glaucoma Progression Detection by Perimetry and Optical Coherence Tomography.Research square · 2024Article
- Impact of Social Vulnerability Index on the Development of Severe Visual Impairment or Blindness From Glaucoma.American journal of ophthalmology · 2024Article
- Racial-ethnic disparities in concurrent rates of peripapillary & macular OCT parameters among a large glaucomatous clinical population.Eye (London, England) · 2024Article
- Short-term Detection of Fast Progressors in Glaucoma: The Fast Progression Assessment through Clustered Evaluation (Fast-PACE) Study.Ophthalmology · 2024Article
- Estimating the Distribution of True Rates of Visual Field Progression in Glaucoma.Translational vision science & technology · 2024Article
- A Bayesian Hierarchical Spatial Longitudinal Model Improves Estimation of Local Macular Rates of Change in Glaucomatous Eyes.Translational vision science & technology · 2024Article
- Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma.Translational vision science & technology · 2023Article
- Fast Progressors in Glaucoma: Prevalence Based on Global and Central Visual Field Loss.Ophthalmology · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
purposeTo compare the ability of linear mixed models with different random effect distributions to estimate rates of visual field loss in glaucoma patients.
methodsEyes with five or more reliable standard automated perimetry (SAP) tests were identified from the Duke Glaucoma Registry. Mean deviation (MD) values from each visual field and associated timepoints were collected. These data were modeled using ordinary least square (OLS) regression and linear mixed models using the Gaussian, Student's t, or log-gamma (LG) distributions as the prior distribution for random effects. Model fit was compared using the Watanabe-Akaike information criterion (WAIC). Simulated eyes of varying initial disease severity and rates of progression were created to assess the accuracy of each model in predicting the rate of change and likelihood of declaring progression.
resultsA total of 52,900 visual fields from 6558 eyes of 3981 subjects were included. Mean follow-up period was 8.7 ± 4.0 years, with an average of 8.1 ± 3.7 visual fields per eye. The LG model produced the lowest WAIC, demonstrating optimal model fit. In simulations, the LG model declared progression earlier than OLS (P < 0.001) and had the greatest accuracy in predicted slopes (P < 0.001). The Gaussian model significantly underestimated rates of progression among fast and catastrophic progressors.
conclusionsLinear mixed models using the LG distribution outperformed conventional approaches for estimating rates of SAP MD loss in a population with glaucoma. TRANSLATIONAL RELEVANCE: Use of the LG distribution in models estimating rates of change among glaucoma patients may improve their accuracy in rapidly identifying progressors at high risk for vision loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.